SEC Form 3 · accession 0001144204-18-012948
Juno Therapeutics, Inc. · JUNO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Mar 5, 2018
Accepted (ET)
Mar 6, 2018 · 8:01 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001594864
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 11,109,160 | I | See Footnote | |
| Common StockF2 | holding | — | — | — | 88,118,707 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares are owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation ("Celgene").
- F2These shares are owned directly by Blue Magpie Corporation, a wholly-owned subsidiary of Celgene.